ClinicalTrials.gg
RecruitingNCT07068126LMICsUpdated Jul 16, 2025

Management of Children With Persistent ITP, A Novel Approach

An interventional study of Mini-Pool IVIG in Persistent Immune Thrombocytopenia, sponsored by Assiut University. Recruiting at 3 sites in Egypt. Open to participants aged 1 Year to 10 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Jan 2025, registered Jul 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
1 Year to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University — 7 open to participants now, 7 under way, none of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Assiut University.

Started
2025
with 2 others
No phase
3 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University, this one is one of 3 that started in 2025, is one of 3 with no phase, and was the 13th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Purpura, Thrombocytopenic, Idiopathic by Assiut University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP). ITP is a condition that causes low platelet levels and increases the risk of bleeding. The main questions this study aims to answer are:

Can mini-pool IVIG raise platelet levels in children with persistent ITP?

Can it reduce bleeding episodes and hospital visits?

What side effects, if any, are seen with this treatment?

There is no comparison group in this study. All participants will receive mini-pool IVIG, which is made from small pools of donated plasma using a cost-effective process.

Participants will:

Receive one dose of mini-pool IVIG through a vein over 6 to 8 hours

Receive follow-up doses every 2 to 4 weeks for up to 5 doses, based on their platelet count

Have regular blood tests and checkups during the study and for 6 months after treatment

Report on bleeding episodes, physical activity, school attendance, and side effects

Read the detailed description

Immune thrombocytopenia (ITP) is an autoimmune condition where the immune system destroys platelets, leading to low platelet counts and increased risk of bleeding. Persistent ITP is defined as ongoing thrombocytopenia lasting 3 to 12 months after initial diagnosis. Children with persistent ITP who lose their response to first-line treatments, such as steroids or standard intravenous immunoglobulin (IVIG), have limited therapeutic options, especially in low- and middle-income countries, due to the high cost of commercial IVIG preparations.

Mini-pool IVIG is produced from small pools of plasma collected locally, using a validated process with virus inactivation and IgG purification steps. This method enables safe, cost-effective preparation of IVIG in resource-limited settings. Prior research has shown that mini-pool IVIG is effective and well-tolerated in acute pediatric ITP, but its role as a second-line therapy for persistent ITP has not been evaluated.

This multicenter, prospective clinical trial will enroll 20 children aged 1 to 10 years with persistent ITP at three tertiary care pediatric hematology centers in Egypt. Participants will receive a loading dose of mini-pool IVIG at 1 g/kg, followed by maintenance doses of 0.5 g/kg every 2 to 4 weeks for up to five additional doses, with dose intervals adjusted based on platelet counts.

Throughout the study, participants will undergo regular blood counts, bleeding assessments using the Bleeding Assessment Tool (BAT), and monitoring for infusion-related or delayed adverse events. Data on school attendance, physical activity, and patient or family satisfaction will also be collected.

Responses to therapy will be classified as complete response (CR), response (R), or no response (NR) based on platelet count thresholds and bleeding status, with response duration measured from achievement of CR or R to loss of response. Participants achieving sustained response off therapy (SRoT) or response off therapy (RoT) during the 6-month post-treatment follow-up will be identified to evaluate durability of treatment effects.

This study aims to provide evidence on the safety and efficacy of mini-pool IVIG as a second-line therapy for persistent pediatric ITP, potentially offering an affordable and effective treatment alternative in settings where standard IVIG is inaccessible due to cost.

03

Conditions studied

  • Persistent Immune Thrombocytopenia
04

Who can participate

Ages eligible
1 Year to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Age 1 - 10 years

  • Gender: Males and Females
  • Persistent ITP according to ASH definition
  • No history of treatment with thrombopoietin agonists

Exclusion Criteria:-History of severe drug adverse events to IVIG

  • Previous history of ICH
  • Difficult venous access
  • Congenital thrombocytopenia, secondary ITP and non-immune thrombocytopenia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Mini-Pool IVIG Treatment Arm

    Participants in this arm will receive mini-pool intravenous immunoglobulin (IVIG) as second-line therapy for persistent immune thrombocytopenia (ITP). Treatment includes a loading dose of 1 g/kg infused over 6-8 hours, followed by maintenance doses of 0.5 g/kg given every 2 to 4 weeks for up to five additional doses. The dosing interval is adjusted based on each participant's platelet count. Participants will have regular blood tests and clinical assessments to monitor platelet levels, bleeding episodes, and treatment safety.

    Biological: Mini-Pool IVIG

Interventions

  • BiologicalMini-Pool IVIG

    Mini-pool intravenous immunoglobulin (IVIG) is a plasma-derived biologic prepared from small pools of locally donated human plasma using a validated, virus-inactivated, closed-system process. Each participant will receive a loading dose of 1 g/kg infused intravenously over 6-8 hours. Maintenance doses of 0.5 g/kg will be given every 2 to 4 weeks for up to five additional doses, with the dosing schedule adjusted based on platelet count. The preparation contains purified IgG and meets safety standards for sterility and viral inactivation.

06

What researchers measure

Primary outcomes

  1. Bleeding Frequency and Severity

    Number, location, and severity of bleeding episodes assessed using the Bleeding assessed using the ISTH Bleeding Assessment Tool (BAT) score, which evaluates bleeding symptoms across multiple anatomical sites. Each site is scored from 0 to 4, with higher scores indicating more severe bleeding. The total score varies depending on the number and severity of bleeding events.Assessment Tool (BAT) score.

    Time frame: From enrollment through 6 months post-treatment.

  2. Platelet Count Response

    Number of participants achieving complete response (platelet count ≥100×10⁹/L) or response (platelet count ≥30×10⁹/L and at least 2-fold increase from baseline) without bleeding.

    Time frame: Assessed monthly during treatment and for 6 months after last dose.

  3. Frequency of Hospital Admissions Due to Critical Bleeding

    Number of hospital admissions for life-threatening bleeding episodes, excluding admissions solely for IVIG infusion.

    Time frame: From enrollment through 6 months post-treatment.

Secondary outcomes

  1. Adverse Events

    Number and type of infusion-related or delayed adverse events experienced during or after mini-pool IVIG treatment.

    Time frame: From first infusion through 6 months after the last dose.

  2. School Attendance

    Change in days missed from school compared to baseline, as a measure of quality of life.

    Time frame: From enrollment through 6 months post-treatment.

  3. Patient and Family Satisfaction

    Level of satisfaction with mini-pool IVIG treatment as reported by participants and caregivers using a structured satisfaction questionnaire.

    Time frame: Assessed at the end of treatment and at 6-month follow-up.

  4. Sustained Response Off-Therapy (SRoT/RoT)

    number of participants maintaining platelet counts ≥100×10⁹/L (SRoT) or ≥30×10⁹/L without bleeding (RoT) for at least 6 months after completing mini-pool IVIG therapy.

    Time frame: 6 months after last mini-pool IVIG dose.

07

Study locations

3 of 3 sites recruiting
  • Children's hospital - Assiut University
    Asyut, 71515, Egypt
    Recruiting
  • Ain Shams University
    Cairo, 11566, Egypt
    Recruiting
  • Zagazig University, Pediatric departement
    Zagazig, 44519, Egypt
    Recruiting
08

References and documents

Publications

  • 1. Kohli, R. and S. Chaturvedi, Epidemiology and Clinical Manifestations of Immune Thrombocytopenia. Hamostaseologie, 2019. 39(3): p. 238-249. 2. Pietras, N.M., et al., Immune Thrombocytopenia, in StatPearls. 2024, StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.: Treasure Island (FL). 3. Thakur, Y., R.J. Meshram, and A. Taksande, Diagnosis and Management of Immune Thrombocytopenia in Paediatrics: A Comprehensive Review. Cureus, 2024. 16(9): p. e69635. 4. Wang, Z., et al., Sustained response off treatment in eltrombopag for children with persistent/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China. Br J Haematol, 2023. 202(2): p. 422-428. 5. Gotesman, M., et al., Pediatric Immune Thrombocytopenia. Adv Pediatr, 2024. 71(1): p. 229-240. 6. El-Ekiaby, M., et al., Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries. PLoS Negl Trop Dis, 2015. 9(2): p. e0003501. 7. Elalfy, M., et al., A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia. Transfusion, 2017. 57(12): p. 3019-3025. 8. Rodeghiero, F., et al., Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009. 113(11): p. 2386-93.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 16, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Mar 1, 2026
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07068126
Lead sponsor
Assiut University
Responsible party
Mervat A. M. Youssef (Principal investigator, Assiut University) — Principal investigator
First posted
Jul 16, 2025
Start date
Jan 1, 2025
Primary completion
Dec 30, 2025 (estimated)
Completion
Mar 1, 2026 (estimated)
Last update
Jul 16, 2025

Study contacts

Mohsen El Alfy, Professor
Contact
Elalfym@hotmail.com
+201000864343
Laila M Sherief, Professor
Contact
lamesh25@yahoo.com
+201001891964
Mervat M A Youssef, Assistant Professor
principal investigator · Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion